Management of Leukocytosis with Concurrent Anemia

Initial Diagnostic Workup

The American College of Emergency Physicians recommends obtaining C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to assess inflammatory activity, with a strength of evidence level of moderate to high 1, 2
Comprehensive metabolic panel including liver enzymes, renal function, and electrolytes should be obtained immediately, as recommended by the World Journal of Emergency Surgery, with a strength of evidence level of high 1
Serum albumin and pre-albumin should be assessed to evaluate nutritional status and degree of inflammation, as recommended by the World Journal of Emergency Surgery, with a strength of evidence level of moderate 1

The National Comprehensive Cancer Network recommends that patients with WBC >100,000/μL be considered a medical emergency and require immediate intervention, with a strength of evidence level of high 3, 4
Aggressive IV hydration (2.5-3 liters/m²/day) should be initiated immediately to prevent tumor lysis syndrome and maintain organ perfusion, as recommended by the Praxis Medical Insights, with a strength of evidence level of high 3

If infection/inflammation is suspected, the Infectious Diseases Society of America recommends ruling out Clostridium difficile and other infectious causes with stool cultures and toxin testing, with a strength of evidence level of high 1
The American College of Rheumatology recommends addressing underlying inflammatory conditions, such as inflammatory bowel disease or Adult-Onset Still's Disease, with a strength of evidence level of moderate to high 1, 2
If hematologic malignancy is suspected, the National Comprehensive Cancer Network recommends immediate hematology/oncology referral, with a strength of evidence level of high 5, 6
For suspected acute promyelocytic leukemia (APL), the American Society of Hematology recommends initiating ATRA immediately, even before molecular confirmation, with a strength of evidence level of high 7, 4

The American College of Emergency Physicians recommends not delaying treatment while awaiting confirmatory testing if hyperleukocytosis or APL is suspected, with a strength of evidence level of high 7, 4
The National Comprehensive Cancer Network recommends not performing leukapheresis in APL patients due to hemorrhage risk, with a strength of evidence level of high 4, 3
The Praxis Medical Insights recommends not overlooking tumor lysis syndrome risk in patients with rapidly rising WBC and falling RBC, with a strength of evidence level of moderate to high 3

The American Heart Association recommends examining CBC with differential to assess for left shift, blast cells, and degree of anemia in patients with leukocytosis and concurrent anemia 8
The National Comprehensive Cancer Network suggests measuring LDH and haptoglobin to assess for hemolysis in patients with leukocytosis and anemia 9

The American Society of Hematology recommends that if blast cells are present on peripheral smear, it represents a medical emergency requiring same-day hematology referral, and if APL is suspected, initiate ATRA immediately without waiting for molecular confirmation 10
The Infectious Diseases Society of America suggests that elevated band count >1500/mm³ has the highest likelihood ratio (14.5) for bacterial infection, and left shift (>6% bands) with neutrophils >90% strongly suggests bacterial infection even with normal total WBC 11

The American Society of Clinical Oncology recommends immediate hematology/oncology referral for suspected hematologic malignancy, and if APL is suspected, start ATRA 45 mg/m²/day divided twice daily immediately 10
The European Society for Medical Oncology suggests that for hyperleukocytosis (WBC >10×10⁹/L) in APL, add cytoreductive chemotherapy (idarubicin 12 mg/m² or gemtuzumab ozogamicin 6-9 mg/m²) without delay 10

The Infectious Diseases Society of America recommends treating underlying infection with appropriate antimicrobials in patients with reactive leukocytosis 11
The American Society of Hematology suggests supportive care for anemia, including consideration of erythropoietic stimulating agents if Hgb ≤10 g/dL and EPO ≤500 mU/dL 12

The European Hematology Association recommends hydroxyurea as first-line for cytoreduction to control proliferative cells and reduce organomegaly in patients with CMML 12
The American Society of Hematology suggests considering allogeneic stem cell transplant in eligible patients with CMML, as this is the only curative option 12